GridAI Technologies Corp., formerly known as Entero Therapeutics, Inc., is a diversified technology and life sciences company operating through two principal areas: (i) energy orchestration and grid optimization software solutions through our subsidiary Grid AI Corp. and (ii) legacy biopharmaceutical development activities centered on Adrulipase for the treatment of exocrine pancreatic insufficiency.
Exocrine pancreatic insufficiency (EPI) in cystic fibrosis(Phase 2)
Exocrine pancreatic insufficiency (EPI) in chronic pancreatitis(Phase 2)
Status note Continuing legacy biopharma focus. Phase 2b pilot monotherapy bridging study reported results Jul 2023; development path under evaluation, subject to available capital and strategic priorities. Company core strategy is now data center energy orchestration.
Niclosamide
Stage not disclosed · TerminatedModality: small molecule (oral)
Indications
not disclosed(Stage not disclosed)
Status note Program discontinued; company exploring strategic alternatives.
Capeserod
Stage not disclosed · TerminatedModality: small molecule
Target 5-HT4 receptor
Partnerships Sanofi: license in-licensed Sep 2023, terminated Feb 2025; no further payments
Indications
Gastrointestinal indications(Stage not disclosed)
Status note Selective 5-HT4 receptor partial agonist. License terminated and program discontinued in 2025.
Per-asset detail extracted from the 10-Q filed 2026-08-21. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.